What are the current legal bottlenecks for telemedicine platforms trying to offer asynchronous weight loss medication prescriptions across state lines with the recent DEA rule changes?
Download run
Fan-out diagram
The searches the AI actually ran for this prompt.
SEED QUERY
What are the current legal bottlenecks for telemedicine platforms trying to offer asynchronous weight loss medication prescriptions across state lines with the recent DEA rule changes?
3 real searches · 1 real-search pass
DEA 2026 telemedicine prescribing rule special registration final rule status October 2026 controlled substances extensionGoogle ↗
OBSERVED
state medical board asynchronous telehealth prescribing GLP-1 weight loss medications cross state lines licensure standard of care 2026Google ↗
OBSERVED
FDA compounded semaglutide tirzepatide shortage 2025 2026 enforcement policy telehealthGoogle ↗
OBSERVED
Badge and edge weight = share of passes that produced the query. Hover a query for its intent and routing format.
Query classes
Google's semantic query class for every sub-query: what kind of answer each search is after, simulated vs real.
Classifying 3 queries…
Searches and sources
ChatGPT3 real searches · gpt-6
DEA 2026 telemedicine prescribing rule special registration final rule status October 2026 controlled substances extension Google ↗
state medical board asynchronous telehealth prescribing GLP-1 weight loss medications cross state lines licensure standard of care 2026 Google ↗
FDA compounded semaglutide tirzepatide shortage 2025 2026 enforcement policy telehealth Google ↗
- HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026 · hhs.gov
- Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications, 61301-61306 [2025-24123] :: Drug Enforcement Administration :: Department Of Justice :: Regulation Tracker :: Justia · regulations.justia.com
- Licensing across state lines · telehealth.hhs.gov
- Federation of State Medical Boards · fsmb.org
- Prescribing controlled substances via telehealth · telehealth.hhs.gov
- Diversion Control Division · deadiversion.usdoj.gov
- EO 12866 Meetings Search Results · reginfo.gov
- DEA Gets Closer to Finalizing Telemedicine Special Registration - NASCSA | National Association of State Controlled Substances Authorities · nascsa.org
- Chapter 05 Telehealth · regs.maryland.gov
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize · fda.gov
- FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List · fda.gov
- FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s · fda.gov
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss · fda.gov
- New Requirements for Nonresident Pharmacies · pharmacy.ca.gov
- DEA Diversion Control Division · deadiversion.usdoj.gov
- Reginfo.gov · reginfo.gov
- Federation of State Medical Boards · fsmb.org
- FDA · fda.gov
Queries
3 queries · click a column to sort
| Query / type | Search | Intent | Query class | Routing format | Cluster | Freq ↓ | Weight |
|---|---|---|---|---|---|---|---|
DEA 2026 telemedicine prescribing rule special registration final rule status October 2026 controlled substances extension OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 | |
state medical board asynchronous telehealth prescribing GLP-1 weight loss medications cross state lines licensure standard of care 2026 OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 | |
FDA compounded semaglutide tirzepatide shortage 2025 2026 enforcement policy telehealth OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 |